{"id":27215,"date":"2025-01-27T04:30:00","date_gmt":"2025-01-26T20:30:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=27215"},"modified":"2025-01-27T06:09:15","modified_gmt":"2025-01-26T22:09:15","slug":"clin-infect-dis%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9arestore%e7%a0%94%e7%a9%b6%e4%b8%ad%e6%8e%a5%e5%8f%97%e7%91%9e%e6%89%8e%e8%8a%ac%e5%87%80%e6%88%96%e5%8d%a1%e6%b3%8a%e8%8a%ac%e5%87%80","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=27215","title":{"rendered":"[Clin Infect Dis\u53d1\u8868\u8bba\u6587]\uff1aReSTORE\u7814\u7a76\u4e2d\u63a5\u53d7\u745e\u624e\u82ac\u51c0\u6216\u5361\u6cca\u82ac\u51c0\u968f\u673a\u5206\u7ec4\u524d\u5ff5\u73e0\u83cc\u57f9\u517b\u9633\u6027\u60a3\u8005\u7684\u6cbb\u7597\u9884\u540e"},"content":{"rendered":"\n

Treatment Outcomes Among Patients With a Positive Candida<\/em> Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study <\/h1>\n\n\n\n

Alex Soriano,  Patrick M Honore,  Oliver A Cornely,  et al<\/h3>\n\n\n\n

Clinical Infectious Diseases<\/em>, Volume 79, Issue 3, 15 September 2024, Pages 672\u2013681, https:\/\/doi.org\/10.1093\/cid\/ciae363<\/a><\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

Background<\/p>\n\n\n\n

Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and\/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial (NCT03667690). We conducted preplanned subgroup analyses for patients with a positive culture close to randomization in ReSTORE.<\/p>\n\n\n\n

Methods<\/p>\n\n\n\n

ReSTORE was a multicenter, double-blind, double-dummy, randomized trial in patients aged \u226518 years with candidemia and\/or IC treated with once-weekly intravenous rezafungin (400 mg\/200 mg) or once-daily intravenous caspofungin (70 mg\/50 mg). This analysis comprised patients with a positive blood culture drawn between 12 hours before and 72 hours after randomization or a positive culture from another normally sterile site sampled between 48 hours before and 72 hours after randomization. Efficacy endpoints included day 30 ACM, day 14 global cure rate, and day 5 and 14 mycological response. Adverse events were evaluated.<\/p>\n\n\n\n

Results<\/p>\n\n\n\n

This analysis included 38 patients randomized to rezafungin and 46 to caspofungin. In the rezafungin and caspofungin groups, respectively, day 30 ACM was 26.3% and 21.7% (between-group difference [95% confidence interval], 4.6% [\u221213.7%, 23.5%]), day 14 global response was 55.3% and 50.0% (between-group difference, 5.3% [\u221216.1%, 26.0%]), and day 5 mycological eradication was 71.1% and 50.0% (between-group difference, 21.1% [\u22120.2%, 40.2%]). Safety was comparable between treatments.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions<\/p>\n\n\n\n

These findings support the efficacy and safety of rezafungin compared with caspofungin for the treatment of candidemia and\/or IC in patients with a positive culture close to randomization, with potential early treatment benefits for rezafungin.<\/p>\n","protected":false},"excerpt":{"rendered":"

Treatment Outcomes Among Patients With a Positive  […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27215"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27215"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27215\/revisions"}],"predecessor-version":[{"id":27615,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27215\/revisions\/27615"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}